

L Number	Hits	Search Text	DB	Time stamp
2	3	pyrazolyl with (quinazolin or quinazoline) with amino	USPAT; US-PGPUB	2003/05/13 16:44
3	24	pyrazolyl with (pyrimidin or pyrimidine) with amino	USPAT; US-PGPUB	2003/05/13 16:45

9AST

10/026, 967

10/ 026,967

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Jun 03 New e-mail delivery for search results now available  
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 11 Oct 24 BEILSTEIN adds new search fields  
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 14 Nov 25 More calculated properties added to REGISTRY  
NEWS 15 Dec 04 CSA files on STN  
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 17 Dec 17 TOXCENTER enhanced with additional content  
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 20 Feb 13 CANCERLIT is no longer being updated  
NEWS 21 Feb 24 METADEX enhancements  
NEWS 22 Feb 24 PCTGEN now available on STN  
NEWS 23 Feb 24 TEMA now available on STN  
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 25 Feb 26 PCTFULL now contains images  
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 27 Mar 19 APOLLIT offering free connect time in April 2003  
NEWS 28 Mar 20 EVENTLINE will be removed from STN  
NEWS 29 Mar 24 PATDPAFULL now available on STN  
NEWS 30 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 31 Apr 11 Display formats in DGENE enhanced  
NEWS 32 Apr 14 MEDLINE Reload  
NEWS 33 Apr 17 Polymer searching in REGISTRY enhanced  
NEWS 34 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS  
NEWS 35 Apr 21 New current-awareness alert (SDI) frequency in  
WPIDS/WPINDEX/WPIX  
NEWS 36 Apr 28 RDISCLOSURE now available on STN  
NEWS 37 May 05 Pharmacokinetic information and systematic chemical names  
added to PHAR  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN

10/ 026,967

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:53:56 ON 12 MAY 2003

=> file reg

COST IN U.S.: DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:54:06 ON 12 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2003 HIGHEST RN 514167-89-6

DICTIONARY FILE UPDATES: 11 MAY 2003 HIGHEST RN 514167-89-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10026967.str


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

10/ 026,967



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 13:54:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 742 TO ITERATE

100.0% PROCESSED 742 ITERATIONS

76 ANSWERS

SEARCH TIME: 00.00.01

L2 76 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 13:54:32 ON 12 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 May 2003 VOL 138 ISS 20

FILE LAST UPDATED: 11 May 2003 (20030511/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3

4 L2



=&gt; d 13 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:615605 CAPLUS

DOCUMENT NUMBER: 137:169539

TITLE: Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Charrier, Jean-Damien; Golec, Julian M. C.; Miller, Andrew; Knegetel, Ronald

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 335 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:




D.I.B.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062789	A1	20020815	WO 2001-US51031	20011219
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
US 2003004161	A1	20030102	US 2001-26975	20011219
US 2003036543	A1	20030220	US 2001-25164	20011219
US 2003055068	A1	20030320	US 2001-26967	20011219
US 2003078275	A1	20030424	US 2001-27001	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 2003022885	A1	20030130	US 2001-34019	20011220
PRIORITY APPLN. INFO.:			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427

OTHER SOURCE(S): MARPAT 137:169539

GI

Same priority doc



AB 285 Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(R6')2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliph., (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6', R7 = independently H or aliph.; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6')2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prep'd. However, the claims pertain only to 3-(2-amino-4-pyrimidinylamino)-1H-pyrazoles, i.e. Z1 = Z2 = N, and Q = NH. I are protein kinase inhibitors, esp. of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 .mu.M: GSK-3.beta. (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases assocd. with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438204-86-5P 438204-90-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

10/ 026,967

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438204-86-5 CAPLUS


CN Carbamic acid, [4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-90-1 CAPLUS

CN Glycine, N-(3-methylphenyl)-N-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

IT 438203-14-6P, [2-(3-Chlorophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-28-5P 438204-29-6P, [2-(Methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-30-9P, (5-Methyl-1H-pyrazol-3-yl) [2-[N-methyl-N-(pyridin-3-ylmethyl)amino]quinazolin-4-yl]amine 438204-31-0P, (5-Methyl-1H-pyrazol-3-yl) (2-phenylaminoquinazolin-4-yl)amine 438204-32-1P, (2-Benzylaminoquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine 438204-33-2P, (2-Cyclohexylaminoquinazolin-4-yl) (5-


methyl-1H-pyrazol-3-yl)amine 438204-34-3P, [2-(2,3-Dihydrobenzo[1,4]dioxin-6-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-35-4P 438204-36-5P, [2-(1H-Indazol-6-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-37-6P 438204-38-7P, [2-(4-Chlorophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-39-8P, [2-(4-Fluorobenzylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-40-1P 438204-41-2P 438204-42-3P, [2-(3-Hydroxyphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-43-4P, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-phenylamino)quinazolin-4-yl)amine 438204-44-5P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-methylphenylamino)quinazolin-4-yl]amine 438204-45-6P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(6-methoxypyridin-3-ylamino)quinazolin-4-yl]amine 438204-46-7P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(indan-5-ylamino)quinazolin-4-yl]amine 438204-47-8P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(1H-indol-6-ylamino)quinazolin-4-yl]amine 438204-48-9P, [2-(4-Acetamido-3-methylphenylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine 438204-49-0P, [2-(4-Chloro-3-methylphenylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine 438204-50-3P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(4-ethylphenylamino)quinazolin-4-yl]amine 438204-51-4P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(4-propylphenylamino)quinazolin-4-yl]amine 438204-52-5P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-[4-(2-hydroxyethyl)phenylamino]quinazolin-4-yl]amine 438204-53-6P, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-phenethylamino)quinazolin-4-yl)amine 438204-54-7P, [2-(2-Cyclohexylethylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine 438204-55-8P 438204-56-9P 438204-57-0P, [2-(Benzothiazol-6-ylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine 438204-58-1P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3,4-dimethylphenylamino)quinazolin-4-yl]amine 438204-59-2P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(2-phenoxyethylamino)quinazolin-4-yl]amine 438204-60-5P 438204-62-7P 438204-63-8P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(1H-indazol-5-ylamino)quinazolin-4-yl]amine 438204-64-9P 438204-65-0P 438204-66-1P, [2-(3-Carboxyphenylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine 438204-67-2P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-ethylphenylamino)quinazolin-4-yl]amine 438204-68-3P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(2,3-dimethylphenylamino)quinazolin-4-yl]amine 438204-69-4P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3,4-dimethoxyphenylamino)quinazolin-4-yl]amine 438204-70-7P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-methoxyphenylamino)quinazolin-4-yl]amine 438204-71-8P, (5-Methyl-1H-pyrazol-3-yl) (2-phenylamino-5,6,7,8-tetrahydroquinazolin-4-yl)amine 438204-72-9P, [2-(Biphenyl-3-ylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine 438204-73-0P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-phenylprop-1-ylamino)quinazolin-4-yl]amine 438204-74-1P, [2-(4-Acetamido-3-methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-75-2P, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(indan-2-ylamino)quinazolin-4-yl]amine 438204-76-3P, [2-(3-Methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-77-4P, [2-(2-Chloro-5-methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-78-5P 438204-79-6P, [2-(Benzothiazol-6-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-80-9P, [2-(3,4-Dimethylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-81-0P, [2-(3-Ethylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-82-1P, [2-(3-Methoxyphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-83-2P, [2-(4-Acetamido-3-cyanophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-84-3P, [2-(2-Methoxybiphenyl-5-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-85-4P,

[2-(4-Acetamidophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438204-87-6P**, [2-(4-Cyanophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438204-88-7P 438204-89-8P**,  
 [2-(Biphenyl-3-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438204-91-2P 438204-92-3P**, [2-(4-Aminophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438204-93-4P**, [2-(4-Bromophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438204-94-5P 438204-95-6P**,  
 (5-Ethyl-1H-pyrazol-3-yl) [2-(5-ethyl-1H-pyrazol-3-ylamino)quinazolin-4-yl] amine **438205-04-0P**, [2-(4-Chlorophenylamino)-5,6,7,8-tetrahydroquinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438205-05-1P**, (5-Methyl-1H-pyrazol-3-yl) (2-phenylamino-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl) amine **438205-06-2P**,  
 [2-(Benzimidazol-2-ylamino)-7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-07-3P**,  
 [7-Benzyl-2-phenylamino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-08-4P**, [6-Benzyl-2-(4-chlorophenylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-09-5P**, [2-(Benzimidazol-2-ylamino)-6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-10-8P**, [6-Benzyl-2-phenylamino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-11-9P**, (5-Methyl-1H-pyrazol-3-yl) - (2-phenylamino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-14-6 CAPLUS

CN 2,4-Quinazolin-2-amine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-28-5 CAPLUS

CN Benzeneethanol, 2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-29-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-30-9 CAPLUS

CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-  
pyridinylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-31-0 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI)  
(CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-32-1 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-33-2 CAPLUS

CN 2,4-Quinazolinediamine, N2-cyclohexyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI)  
(CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-34-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-35-4 CAPLUS

CN 2,4-Quinazolinediamine, N2-(cyclohexylmethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-36-5 CAPLUS

CN 2,4-Quinazolinediamine, N2-1H-indazol-6-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-37-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-38-7 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-39-8 CAPLUS


CN 2,4-Quinazolinediamine, N2-[(4-fluorophenyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-40-1 CAPLUS


CN Benzenecetonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-41-2 CAPLUS

CN Benzenemethanol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-42-3 CAPLUS

10/ 026,967


CN Phenol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-43-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-44-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-45-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-46-7 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-47-8 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indol-6-yl- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-48-9 CAPLUS


CN Acetamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-methylphenyl]-2-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-49-0 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-chloro-3-methylphenyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-50-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-51-4 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-propylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-52-5 CAPLUS


CN Benzeneethanol, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-53-6 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-54-7 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-cyclohexylethyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-55-8 CAPLUS

CN Acetic acid, [4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-56-9 CAPLUS

CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-57-0 CAPLUS


CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-cyclopropyl-1H-pyrazol-3-yl) - (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-58-1 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethylphenyl) - (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-59-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-60-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-62-7 CAPLUS

CN Benzeneacetic acid, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-63-8 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indazol-5-yl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-64-9 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-65-0 CAPLUS


CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-66-1 CAPLUS

CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-67-2 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-ethylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-68-3 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-69-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-70-7 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-71-8 CAPLUS

CN 2,4-Quinazolinediamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-72-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-73-0 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-74-1 CAPLUS


CN Acetamide, N-[2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-75-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-76-3 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)






10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-77-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-chloro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-78-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-79-6 CAPLUS

CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-80-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-(3,4-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-81-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-ethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-82-1 CAPLUS

10/ 026,967


CN 2,4-Quinazolinediamine, N2-(3-methoxyphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-83-2 CAPLUS


CN Acetamide, N-[2-cyano-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-84-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(6-methoxy[1,1'-biphenyl]-3-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-85-4 CAPLUS


CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-87-6 CAPLUS

CN Benzonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-88-7 CAPLUS


CN 6H-Dibenzo[b,d]pyran-6-one, 4a,10b-dihydro-2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-89-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-91-2 CAPLUS

CN Benzeneacetic acid, 2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-92-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-aminophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-93-4 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-bromophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-94-5 CAPLUS


CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-95-6 CAPLUS

CN 2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-04-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-05-1 CAPLUS


CN 5H-Cycloheptapyrimidine-2,4-diamine, 6,7,8,9-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-06-2 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-07-3 CAPLUS



10/ 026,967


CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-08-4 CAPLUS

CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-09-5 CAPLUS

CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-10-8 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-11-9 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/ 026,967

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:575069 CAPLUS

DOCUMENT NUMBER: 137:109292

TITLE: Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Golec, Julian; Kay, David; Knegtel, Ronald; Patel, Sanjay

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 337 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059111	A2	20020801	WO 2001-US51120	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003004161	A1	20030102	US 2001-26975	20011219
US 2003036543	A1	20030220	US 2001-25164	20011219
US 2003055068	A1	20030320	US 2001-26967	20011219
US 2003078275	A1	20030424	US 2001-27001	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 2003022885	A1	20030130	US 2001-34019	20011220

PRIORITY APPLN. INFO.:

US 2000-257887P P 20001221




US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 137:109292

GI

D.I.T.

same priority date



AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliph., (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliph.; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepd. I are protein kinase inhibitors, esp. of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 .mu.M: GSK-3.beta. (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases assocd. with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438204-86-5P 438204-90-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and

10/ 026,967

Alzheimer's disease)

RN 438204-86-5 CAPLUS


CN Carbamic acid, [4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-90-1 CAPLUS

CN Glycine, N-(3-methylphenyl)-N-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

IT 438203-14-6P 438204-28-5P 438204-29-6P  
438204-30-9P 438204-31-0P 438204-32-1P  
438204-33-2P 438204-34-3P 438204-35-4P  
438204-36-5P 438204-37-6P 438204-38-7P  
438204-39-8P 438204-40-1P 438204-41-2P  
438204-42-3P 438204-43-4P 438204-44-5P  
438204-45-6P 438204-46-7P 438204-47-8P  
438204-48-9P 438204-49-0P 438204-50-3P  
438204-51-4P 438204-52-5P 438204-53-6P  
438204-54-7P 438204-55-8P 438204-56-9P  
438204-57-0P 438204-58-1P 438204-59-2P  
438204-60-5P 438204-62-7P 438204-63-8P


438204-64-9P 438204-65-0P 438204-66-1P  
 438204-67-2P 438204-68-3P 438204-69-4P  
 438204-70-7P 438204-71-8P 438204-72-9P  
 438204-73-0P 438204-74-1P 438204-75-2P  
 438204-76-3P 438204-77-4P 438204-78-5P  
 438204-79-6P 438204-80-9P 438204-81-0P  
 438204-82-1P 438204-83-2P 438204-84-3P  
 438204-85-4P 438204-87-6P 438204-88-7P  
 438204-89-8P 438204-91-2P 438204-92-3P  
 438204-93-4P 438204-94-5P 438204-95-6P  
 438205-04-0P 438205-05-1P 438205-06-2P  
 438205-07-3P 438205-08-4P 438205-09-5P  
 438205-10-8P 438205-11-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as  
 protein kinase inhibitors for treatment of cancer, diabetes, and  
 Alzheimer's disease)

RN 438203-14-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
 (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-28-5 CAPLUS

CN Benzeneethanol, 2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-29-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-30-9 CAPLUS

CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-31-0 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI)  
(CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-32-1 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-33-2 CAPLUS

CN 2,4-Quinazolinediamine, N2-cyclohexyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI)  
(CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-34-3 CAPLUS

CN 2,4-Quinazolinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-(5-methyl-  
1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-35-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(cyclohexylmethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-36-5 CAPLUS

CN 2,4-Quinazolinediamine, N2-1H-indazol-6-yl-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-37-6 CAPLUS

10/ 026,967


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-38-7 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-39-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[(4-fluorophenyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-40-1 CAPLUS


CN Benzenecetonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-41-2 CAPLUS

CN Benzenemethanol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-42-3 CAPLUS

CN Phenol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-43-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-44-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-  
methylphenyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-45-6 CAPLUS

10/ 026,967


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-46-7 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-47-8 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indol-6-yl- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-48-9 CAPLUS


CN Acetamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-49-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chloro-3-methylphenyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-50-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-51-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-propylphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-52-5 CAPLUS


CN Benzeneethanol, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-53-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-54-7 CAPLUS

CN 2,4-Quinazolinediamine, N2-(2-cyclohexylethyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-55-8 CAPLUS

CN Acetic acid, [4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-56-9 CAPLUS


CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-57-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-58-1 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-59-2 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-60-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-thienylmethyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-62-7 CAPLUS


CN Benzeneacetic acid, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-63-8 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indazol-5-yl- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-64-9 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-65-0 CAPLUS

CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-66-1 CAPLUS

CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-67-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-ethylphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-68-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-69-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-70-7 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-71-8 CAPLUS


CN 2,4-Quinazolinediamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-72-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-73-0 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-74-1 CAPLUS

CN Acetamide, N-[2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-

10/ 026,967


quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-75-2 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-76-3 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-77-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-chloro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-78-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-79-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-80-9 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3,4-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-81-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-ethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-82-1 CAPLUS


CN 2,4-Quinazolinediamine, N2-(3-methoxyphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-83-2 CAPLUS

CN Acetamide, N-[2-cyano-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-84-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(6-methoxy[1,1'-biphenyl]-3-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-85-4 CAPLUS

CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-87-6 CAPLUS

CN Benzonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-88-7 CAPLUS

CN 6H-Dibenzo[b,d]pyran-6-one, 4a,10b-dihydro-2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-89-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-91-2 CAPLUS


CN Benzeneacetic acid, 2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-92-3 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-aminophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-93-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-bromophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-94-5 CAPLUS

CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-95-6 CAPLUS

CN 2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA  
INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-04-0 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-05-1 CAPLUS

CN 5H-Cycloheptapyrimidine-2,4-diamine, 6,7,8,9-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*


RN 438205-06-2 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-7-(phenylmethyl)- (9CI) (CA



10/ 026,967


INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-07-3 CAPLUS


CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-08-4 CAPLUS

CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-09-5 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-10-8 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-11-9 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:555487 CAPLUS

DOCUMENT NUMBER: 137:125169

TITLE: Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3

INVENTOR(S): Bebbington, David; Charrier, Jean-Damien; Golec, Julian; Miller, Andrew; Knegt, Ronald

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 333 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057259	A2	20020725	WO 2001-US49401	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG




US 2003004161	A1	20030102	US 2001-26975	20011219
US 2003036543	A1	20030220	US 2001-25164	20011219
US 2003055068	A1	20030320	US 2001-26967	20011219
US 2003078275	A1	20030424	US 2001-27001	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 2003022885	A1	20030130	US 2001-34019	20011220

PRIORITY APPLN. INFO.:

US 2000-257887P P 20001221  
US 2001-286949P P 20010427

OTHER SOURCE(S):  
GI

MARPAT 137:125169



AB The title compds. I [Z1 = N, CR8; Z2 = N. CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliph., (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl, or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepd. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 .mu.M: GSK-3.beta. (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases assocd. with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438204-86-5P 438204-90-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

10/ 026,967

(Preparation); RACT (Reactant or reagent); USES (Uses)  
(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as  
protein kinase inhibitors for treatment of cancer, diabetes, and  
Alzheimer's disease)

RN 438204-86-5 CAPLUS


CN Carbamic acid, [4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-  
quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-90-1 CAPLUS

CN Glycine, N-(3-methylphenyl)-N-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-  
quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

IT 438203-14-6P 438204-28-5P 438204-29-6P  
438204-30-9P 438204-31-0P 438204-32-1P  
438204-33-2P 438204-34-3P 438204-35-4P  
438204-36-5P 438204-37-6P 438204-38-7P  
438204-39-8P 438204-40-1P 438204-41-2P  
438204-42-3P 438204-43-4P 438204-44-5P  
438204-45-6P 438204-46-7P 438204-47-8P  
438204-48-9P 438204-49-0P 438204-50-3P  
438204-51-4P 438204-52-5P 438204-53-6P


438204-54-7P 438204-55-8P 438204-56-9P  
 438204-57-0P 438204-58-1P 438204-59-2P  
 438204-60-5P 438204-62-7P 438204-63-8P  
 438204-64-9P 438204-65-0P 438204-66-1P  
 438204-67-2P 438204-68-3P 438204-69-4P  
 438204-70-7P 438204-71-8P 438204-72-9P  
 438204-73-0P 438204-74-1P 438204-75-2P  
 438204-76-3P 438204-77-4P 438204-78-5P  
 438204-79-6P 438204-80-9P 438204-81-0P  
 438204-82-1P 438204-83-2P 438204-84-3P  
 438204-85-4P 438204-87-6P 438204-88-7P  
 438204-89-8P 438204-91-2P 438204-92-3P  
 438204-93-4P 438204-94-5P 438204-95-6P  
 438205-04-0P 438205-05-1P 438205-06-2P  
 438205-07-3P 438205-08-4P 438205-09-5P  
 438205-10-8P 438205-11-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as  
 protein kinase inhibitors for treatment of cancer, diabetes, and  
 Alzheimer's disease)

RN 438203-14-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
 (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-28-5 CAPLUS


CN Benzeneethanol, 2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-29-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-30-9 CAPLUS

CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-31-0 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI)  
(CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-32-1 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-33-2 CAPLUS

CN 2,4-Quinazolinediamine, N2-cyclohexyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI)  
(CA INDEX NAME)






10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-34-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-35-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(cyclohexylmethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-36-5 CAPLUS


CN 2,4-Quinazolinediamine, N2-1H-indazol-6-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-37-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-38-7 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-39-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[(4-fluorophenyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-40-1 CAPLUS


CN Benzenecetonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-41-2 CAPLUS

CN Benzenemethanol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-42-3 CAPLUS

10/ 026,967


CN Phenol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-43-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-44-5 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-45-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-46-7 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-47-8 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indol-6-yl- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-48-9 CAPLUS

CN Acetamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-49-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chloro-3-methylphenyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-50-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-51-4 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-propylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-52-5 CAPLUS


CN Benzeneethanol, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-53-6 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*



10/ 026,967

RN 438204-54-7 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-cyclohexylethyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-55-8 CAPLUS


CN Acetic acid, [4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-56-9 CAPLUS


CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-57-0 CAPLUS


CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-cyclopropyl-1H-pyrazol-3-yl) - (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-58-1 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethylphenyl) - (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-59-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-60-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-62-7 CAPLUS

CN Benzeneacetic acid, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-63-8 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indazol-5-yl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-64-9 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-65-0 CAPLUS


CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-66-1 CAPLUS

CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-67-2 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-ethylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-68-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-69-4 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-70-7 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-71-8 CAPLUS

CN 2,4-Quinazolinediamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-72-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-73-0 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-74-1 CAPLUS

CN Acetamide, N-[2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-75-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-76-3 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-77-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-chloro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-78-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-79-6 CAPLUS

CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-80-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-(3,4-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-81-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-ethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-82-1 CAPLUS

10/ 026,967


CN 2,4-Quinazolinediamine, N2-(3-methoxyphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-83-2 CAPLUS


CN Acetamide, N-[2-cyano-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-84-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(6-methoxy[1,1'-biphenyl]-3-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-85-4 CAPLUS


CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-87-6 CAPLUS

CN Benzonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-88-7 CAPLUS


CN 6H-Dibenzo[b,d]pyran-6-one, 4a,10b-dihydro-2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-89-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-91-2 CAPLUS

CN Benzeneacetic acid, 2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-92-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-aminophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-93-4 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-bromophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-94-5 CAPLUS


CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-95-6 CAPLUS

CN 2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-04-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-05-1 CAPLUS


CN 5H-Cycloheptapyrimidine-2,4-diamine, 6,7,8,9-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-06-2 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-07-3 CAPLUS

10/ 026,967


CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-08-4 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-09-5 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-10-8 CAPLUS


CN    Pyrido[4,3-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-6-(phenylmethyl)- (9CI)    (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-11-9 CAPLUS

CN    Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI)    (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

DOCUMENT NUMBER: 137:47221  
 TITLE: Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease  
 INVENTOR(S): Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Everitt, Simon; Kay, David; Knegetel, Ronald; Patel, Sanjay  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA  
 SOURCE: PCT Int. Appl., 342 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 14  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050065	A2	20020627	WO 2001-US49140	20011219
WO 2002050065	A3	20021024		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002034047	A5	20020701	AU 2002-34047	20011219
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003004161	A1	20030102	US 2001-26975	20011219
US 2003036543	A1	20030220	US 2001-25164	20011219
US 2003055068	A1	20030320	US 2001-26967	20011219
US 2003078275	A1	20030424	US 2001-27001	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 2003022885	A1	20030130	US 2001-34019	20011220
PRIORITY APPLN. INFO.:			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			WO 2001-US49140	W 20011219

OTHER SOURCE(S): MARPAT 137:47221  
 GI

*same priority file*



AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliph., (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliph.; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prep'd. I are protein kinase inhibitors, esp. of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 .mu.M: GSK-3.beta. (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases assocd. with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438204-86-5P 438204-90-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as

protein kinase inhibitors for treatment of cancer, diabetes, and  
Alzheimer's disease)

RN 438204-86-5 CAPLUS


CN Carbamic acid, [4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-90-1 CAPLUS

CN Glycine, N-(3-methylphenyl)-N-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

IT 438203-14-6P, [2-(3-Chlorophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-28-5P 438204-29-6P, [2-(Methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-30-9P, (5-Methyl-1H-pyrazol-3-yl) [2-[N-methyl-N-(pyridin-3-ylmethyl)amino]quinazolin-4-yl]amine 438204-31-0P, (5-Methyl-1H-pyrazol-3-yl) (2-phenylaminoquinazolin-4-yl)amine 438204-32-1P, (2-Benzylaminoquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine 438204-33-2P, (2-Cyclohexylaminoquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine 438204-34-3P, [2-(2,3-Dihydrobenzo[1,4]dioxin-6-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine 438204-35-4P 438204-36-5P,


[2-(1H-Indazol-6-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-37-6P 438204-38-7P**, [2-(4-Chlorophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-39-8P**, [2-(4-Fluorobenzylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-40-1P 438204-41-2P 438204-42-3P**, [2-(3-Hydroxyphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-43-4P**, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-phenylaminoquinazolin-4-yl)amine  
**438204-44-5P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-methylphenylamino)quinazolin-4-yl]amine  
**438204-45-6P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(6-methoxypyridin-3-ylamino)quinazolin-4-yl]amine  
**438204-46-7P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(indan-5-ylamino)quinazolin-4-yl]amine  
**438204-47-8P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(1H-indol-6-ylamino)quinazolin-4-yl]amine  
**438204-48-9P**, [2-(4-Acetamido-3-methylphenylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine  
**438204-49-0P**, [2-(4-Chloro-3-methylphenylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine  
**438204-50-3P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(4-ethylphenylamino)quinazolin-4-yl]amine  
**438204-51-4P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(4-propylphenylamino)quinazolin-4-yl]amine  
**438204-52-5P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-[4-(2-hydroxyethyl)phenylamino]quinazolin-4-yl]amine  
**438204-53-6P**, (5-Cyclopropyl-1H-pyrazol-3-yl) (2-phenethylaminoquinazolin-4-yl)amine  
**438204-54-7P**, [2-(2-Cyclohexylethylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine  
**438204-55-8P 438204-56-9P 438204-57-0P**, [2-(Benzothiazol-6-ylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine  
**438204-58-1P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3,4-dimethylphenylamino)quinazolin-4-yl]amine  
**438204-59-2P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(2-phenoxyethylamino)quinazolin-4-yl]amine  
**438204-60-5P 438204-62-7P 438204-63-8P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(1H-indazol-5-ylamino)quinazolin-4-yl]amine  
**438204-64-9P 438204-65-0P 438204-66-1P**, [2-(3-Carboxyphenylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine  
**438204-67-2P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-ethylphenylamino)quinazolin-4-yl]amine  
**438204-68-3P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(2,3-dimethylphenylamino)quinazolin-4-yl]amine  
**438204-69-4P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3,4-dimethoxyphenylamino)quinazolin-4-yl]amine  
**438204-70-7P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-methoxyphenylamino)quinazolin-4-yl]amine  
**438204-71-8P**, (5-Methyl-1H-pyrazol-3-yl) (2-phenylamino-5,6,7,8-tetrahydroquinazolin-4-yl)amine  
**438204-72-9P**, [2-(Biphenyl-3-ylamino)quinazolin-4-yl] (5-cyclopropyl-1H-pyrazol-3-yl)amine  
**438204-73-0P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(3-phenylprop-1-ylamino)quinazolin-4-yl]amine  
**438204-74-1P**, [2-(4-Acetamido-3-methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-75-2P**, (5-Cyclopropyl-1H-pyrazol-3-yl) [2-(indan-2-ylamino)quinazolin-4-yl]amine  
**438204-76-3P**, [2-(3-Methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-77-4P**, [2-(2-Chloro-5-methylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-78-5P 438204-79-6P**, [2-(Benzothiazol-6-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-80-9P**, [2-(3,4-Dimethylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-81-0P**, [2-(3-Ethylphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-82-1P**, [2-(3-Methoxyphenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-83-2P**, [2-(4-Acetamido-3-cyanophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-84-3P**, [2-(2-Methoxybiphenyl-5-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-85-4P**, [2-(4-Acetamidophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-87-6P**, [2-(4-Cyanophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl)amine  
**438204-88-7P 438204-89-8P**,

[2-(Biphenyl-3-ylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438204-91-2P 438204-92-3P**, [2-(4-Aminophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438204-93-4P**, [2-(4-Bromophenylamino)quinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438204-94-5P 438204-95-6P**,  
 (5-Ethyl-1H-pyrazol-3-yl) [2-(5-ethyl-1H-pyrazol-3-ylamino)quinazolin-4-yl] amine **438205-04-0P**, [2-(4-Chlorophenylamino)-5,6,7,8-tetrahydroquinazolin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine  
**438205-05-1P**, (5-Methyl-1H-pyrazol-3-yl) (2-phenylamino-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl) amine **438205-06-2P**,  
 [2-(Benzimidazol-2-ylamino)-7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-07-3P**,  
 [7-Benzyl-2-phenylamino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-08-4P**, [6-Benzyl-2-(4-chlorophenylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-09-5P**, [2-(Benzimidazol-2-ylamino)-6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-10-8P**, [6-Benzyl-2-phenylamino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-methyl-1H-pyrazol-3-yl) amine **438205-11-9P**, (5-Methyl-1H-pyrazol-3-yl)-(2-phenylamino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-14-6 CAPLUS

CN 2,4-Quinazolin-2-amine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-28-5 CAPLUS

CN Benzeneethanol, 2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-29-6 CAPLUS


CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-30-9 CAPLUS

CN 2,4-Quinazolinediamine, N2-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-31-0 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI)  
(CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-32-1 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-33-2 CAPLUS

CN 2,4-Quinazolinediamine, N2-cyclohexyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI)  
(CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-34-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-35-4 CAPLUS

CN 2,4-Quinazolinediamine, N2-(cyclohexylmethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-36-5 CAPLUS

CN 2,4-Quinazolinediamine, N2-1H-indazol-6-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-37-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-38-7 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-39-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[(4-fluorophenyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-40-1 CAPLUS


CN Benzenecetonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-41-2 CAPLUS

CN Benzenemethanol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-42-3 CAPLUS

10/ 026,967


CN Phenol, 3-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-43-4 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-phenyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-44-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-45-6 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-46-7 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-47-8 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indol-6-yl- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-48-9 CAPLUS

CN Acetamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-49-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chloro-3-methylphenyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-50-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-51-4 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-propylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-52-5 CAPLUS


CN Benzeneethanol, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-53-6 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

10/ 026,967

RN 438204-54-7 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-cyclohexylethyl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-55-8 CAPLUS

CN Acetic acid, [4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-56-9 CAPLUS

CN Benzeneacetonitrile, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-57-0 CAPLUS


CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-58-1 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethylphenyl)-(9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-59-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-60-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-62-7 CAPLUS

CN Benzeneacetic acid, 4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-63-8 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-1H-indazol-5-yl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-64-9 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-65-0 CAPLUS


CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-66-1 CAPLUS

CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-67-2 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-ethylphenyl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-68-3 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-69-4 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)






\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-70-7 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-71-8 CAPLUS

CN 2,4-Quinazolinediamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-72-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-73-0 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-74-1 CAPLUS

CN Acetamide, N-[2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-75-2 CAPLUS


CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-76-3 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-77-4 CAPLUS


CN 2,4-Quinazolinediamine, N2-(2-chloro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-78-5 CAPLUS

CN 2,4-Quinazolinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-79-6 CAPLUS

CN 2,4-Quinazolinediamine, N2-6-benzothiazolyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-80-9 CAPLUS


CN 2,4-Quinazolinediamine, N2-(3,4-dimethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-81-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(3-ethylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-82-1 CAPLUS

10/ 026,967


CN 2,4-Quinazolinediamine, N2-(3-methoxyphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-83-2 CAPLUS


CN Acetamide, N-[2-cyano-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-84-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(6-methoxy[1,1'-biphenyl]-3-yl)-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-85-4 CAPLUS


CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-87-6 CAPLUS

CN Benzonitrile, 4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-88-7 CAPLUS


CN 6H-Dibenzo[b,d]pyran-6-one, 4a,10b-dihydro-2-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-89-8 CAPLUS

CN 2,4-Quinazolinediamine, N2-[1,1'-biphenyl]-3-yl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-91-2 CAPLUS

CN Benzeneacetic acid, 2-methyl-4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-92-3 CAPLUS


CN 2,4-Quinazolinediamine, N2-(4-aminophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-93-4 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-bromophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-  
(9CI) (CA INDEX NAME)




10/ 026,967

\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-94-5 CAPLUS


CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438204-95-6 CAPLUS

CN 2,4-Quinazolinediamine, N,N'-bis(5-ethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-04-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)


10/ 026,967



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-05-1 CAPLUS


CN 5H-Cycloheptapyrimidine-2,4-diamine, 6,7,8,9-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-06-2 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-07-3 CAPLUS

10/ 026,967


CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-08-4 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-(4-chlorophenyl)-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-09-5 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-10-8 CAPLUS


CN Pyrido[4,3-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 438205-11-9 CAPLUS

CN Pyrido[3,4-d]pyrimidine-2,4-diamine, 5,6,7,8-tetrahydro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-phenyl- (9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

=> d his

10/ 026,967

(FILE 'HOME' ENTERED AT 13:53:56 ON 12 MAY 2003)

FILE 'REGISTRY' ENTERED AT 13:54:06 ON 12 MAY 2003

L1           STRUCTURE UPLOADED  
L2           76 S L1 FUL

FILE 'CAPLUS' ENTERED AT 13:54:32 ON 12 MAY 2003

L3           4 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

19.40

167.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.60

-2.60

STN INTERNATIONAL LOGOFF AT 13:56:11 ON 12 MAY 2003